Application of ligusticum cyclopropyrianum in preparation of medicine for preventing and treating metabolism-related fatty liver diseases

By using cipropanol to inhibit liver fat production and inflammation, and reduce gene expression of metabolic-related fatty liver disease, the problem of limited safety and efficacy of existing therapeutic drugs is solved, and effective prevention and treatment of metabolic-related fatty liver disease is achieved. It has the advantages of safety, low toxicity and low cost.

CN118903110APending Publication Date: 2024-11-08HARBIN MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411144037.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing metabolic-related fatty liver disease treatment drugs have problems with drug safety and tolerance, limited efficacy, lack of individualized treatments and high treatment costs, and ciclopropion has not been reported in this field.

Method used

Cyclopropion is used as the only active ingredient to reduce fasting blood glucose values ​​by inhibiting liver fat production, lipid deposition and liver damage, improve glucose intolerance and insulin resistance, and reduce lipid metabolism, liver inflammation and fibrosis-related gene expression , prepare drugs to prevent and treat metabolic-related fatty liver diseases.

Benefits of technology

Cyclopropyl Alcohol significantly improves liver damage, insulin resistance, glycolipid metabolism disorders, inflammatory damage and fibrosis of metabolic-related fatty liver disease, thus achieving effective prevention and treatment of metabolic-related fatty liver disease, and is safe, low-toxic, and has rich sources. , has huge social and economic benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903110A_ABST
    Figure CN118903110A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of ligusticum cyclopropyrianum in preparation of a medicine for preventing and treating metabolism-related fatty liver diseases. The invention provides an application of ligusticum cyclopropyrianum in preparation of a medicine for preventing and / or treating metabolism-related fatty liver diseases. Research results of the invention show that the ligusticum cyclopropyrianum can improve liver injury, insulin resistance, glycolipid metabolism disorder, inflammatory injury and fibrosis of the metabolism-related fatty liver disease, so that the purpose of preventing and treating the metabolism-related fatty liver disease is achieved, and the ligusticum cyclopropyrianum can be used as a candidate drug for development of drugs for treating the metabolism-related fatty liver disease; the ligusticum cyclopropyl is obtained by deriving, converting and synthesizing ligustilide in bulk traditional Chinese medicinal materials of angelica sinensis and ligusticum wallichii, is rich in source, can be extracted from plants, and is safe, low in toxicity and relatively strong in pharmacological action.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to the application of ciprofloxacin in the preparation of drugs for preventing and treating metabolism-related fatty liver disease. Background Art

[0002] Metabolic associated fatty liver disease (MAFLD) is a chronic liver disease caused by metabolic dysfunction due to multiple factors, which leads to fat deposition and degeneration in the liver. Its pathological features include fatty degeneration of the liver, hepatocellular damage, inflammation and fibrosis. In severe cases, it can further develop into cirrhosis or even liver cancer.

[0003] At present, the therapeutic drugs for MAFLD are mainly divided into two categories: metabolic disorders targeting the pathogenesis of the disease and physiological manifestations targeting the disease. Common ones include insulin sensitizers (metformin and thiazolidinediones), lipid-lowering drugs (fibrates or statins) and drugs for liver disease (vitamin E, ursodeoxycholic acid, etc.). However, long-term use of these drugs will cause corresponding side effects to the liver. Although the US FDA has approved the drug Rezdiffra for the treatment of non-alcoholic fatty liver disease, its actual clinical application effect and potential side effects still need to be closely monitored. The current problems in drug development include: drug safety and tolerability issues; unknown long-term effects; limited efficacy; lack of individualized treatment and high treatment costs.

[0004] Compared with traditional treatment strategies, compounds derived from natural medicinal plants have advantages such as safety, multi-target effects and low cost. Ligustilide belongs to the phthalide class of compounds and is a natural product that is abundantly contained in Chinese medicinal materials such as Angelica sinensis and Ligusticum chuanxiong. It has clear pharmacological activity, but its chemical structure is unstable and its drugability is poor. Highly stable colorless needle-shaped crystals of ciprofloxacin can be obtained through cyclopropylamine derivatization reaction. However, there are no reports on the use of ciprofloxacin in the treatment of metabolic-related fatty liver disease. Summary of the invention

[0005] In view of the problems existing in the prior art, the present invention provides the use of ciprofloxacin in the preparation of a drug for preventing and treating metabolism-related fatty liver disease, which has the advantages of safety, multi-target action and low cost, and has good prospects for clinical application.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0007] The present invention provides the use of ciprofloxacin in preparing a medicament for preventing and / or treating metabolism-related fatty liver disease.

[0008] Preferably, the non-alcoholic fatty liver disease is non-alcoholic fatty liver disease induced by a high-fat diet and / or non-alcoholic fatty liver disease combined with diabetes.

[0009] Preferably, the method for preventing and / or treating metabolic-related fatty liver disease is embodied in at least one of the following aspects:

[0010] 1) Inhibit hepatic lipogenesis, lipid deposition and / or liver damage;

[0011] 2) Reduce fasting blood sugar levels;

[0012] 3) Improve glucose intolerance and insulin resistance;

[0013] 4) Improve fatty degeneration and lipotoxic damage;

[0014] 5) Reduce the expression of genes related to lipid metabolism, liver inflammation and / or fibrosis.

[0015] Preferably, the lipid metabolism related genes include one or more of Fasn, Fabp1, Srebp-1c, Hmgcr, ACCα, Scd1 and Cd36.

[0016] Preferably, the genes related to liver inflammation include one or more of IL-6, IL-1b, TNF-α, Cxcl10 and Ccl2.

[0017] Preferably, the profibrosis-related genes include one or more of Tgf-β1, Col1a1 and Timp1.

[0018] Preferably, ciprofloxacin is the only active ingredient in the drug.

[0019] Preferably, the drug comprises pharmaceutically acceptable excipients, which include one or more of surfactants, buffer substances, disintegrants, binders, fillers, lubricants, solubilizers, flavoring agents and colorants.

[0020] Preferably, the drug is in the form of tablets, pills, capsules, granules, powders or liquids.

[0021] Preferably, the drug is administered orally, subcutaneously, intravenously or in a sustained-release form.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] (1) The research results of the present invention show that ciprofloxacin improves liver damage, insulin resistance, glucose and lipid metabolism disorders, inflammatory damage and fibrosis of metabolic-related fatty liver disease by inhibiting liver fat production, lipid deposition and / or liver damage; lowering fasting blood glucose levels; improving glucose intolerance and insulin resistance; improving fatty degeneration and fat toxicity damage; and lowering the expression of genes related to lipid metabolism, liver inflammation and / or fibrosis, thereby achieving the purpose of preventing and treating metabolic-related fatty liver disease. The drug can be used as a candidate drug for the development of drugs for the treatment of metabolic-related fatty liver disease.

[0024] (2) The medicine for preventing and treating metabolic-related fatty liver disease provided by the present invention is safe, low-toxic, and has a strong pharmacological effect. Its raw material source is abundant and can be extracted from plants, and it can generate huge social and economic benefits in a relatively short period of time. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Effects of ciprofloxacin on body weight and liver-to-body ratio in mice with high-fat fructose-induced fatty liver.

[0026] Figure 2 Effects of Ligusticum chuanxiong on glucose tolerance in mice with high-fat fructose-induced fatty liver.

[0027] Figure 3 Effects of Ligusticum chuanxiong on insulin resistance in mice with high-fat fructose-induced fatty liver.

[0028] Figure 4 The effect of ciprofloxacin on serum ALT and AST indicators in mice with fatty liver induced by high-fat fructose.

[0029] Figure 5 This study is about the effects of ciprofloxacin on liver TG indexes in mice with fatty liver induced by high-fat fructose.

[0030] Figure 6 H&E staining and Oil Red O staining of the liver of mice with fatty liver induced by high-fat fructose were observed for pathological sections of ciprofloxacin (10×).

[0031] Figure 7 To investigate the effects of ciprofloxacin on the expression of genes and proteins related to liver lipid metabolism in mice with high-fat fructose-induced fatty liver.

[0032] Figure 8 Observation on the effect of ciprofloxacin on the expression of CD68, a monocyte marker in the liver of mice with fatty liver induced by high-fat fructose

[0033] (50μm).

[0034] Fig. 9 To investigate the effects of ciprofloxacin on the expression of genes and proteins related to liver inflammation in mice with high-fat fructose-induced fatty liver.

[0035] Fig.10 This is the Sirius red-stained pathological section observation of the liver of mice with fatty liver induced by high-fat fructose (50μm).

[0036] Fig.11 To investigate the effect of ciprofloxacin on the expression of liver fibrosis-related genes in mice with high-fat fructose-induced fatty liver.

[0037] Fig.12 To investigate the effects of ciprofloxacin on body weight and liver-to-body ratio in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0038] Fig.13 To investigate the effects of ciprofloxacin on liver size and weight in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0039] Fig.14 To investigate the effects of ciprofloxacin on fasting blood glucose in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0040] Fig.15 To investigate the effect of ciprofloxacin on glucose tolerance in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0041] Fig.16 To investigate the effect of ciprofloxacin on insulin resistance in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0042] Fig.17 To investigate the effect of ciprofloxacin on serum ALT and AST in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0043] Fig.18 To investigate the effects of ciprofloxacin on liver TG indexes in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0044] Fig.19 H&E staining pathological section observation of the liver of mice with diabetic fatty liver induced by STZ combined with high-fat diet (10×).

[0045] Fig. 20 To investigate the effect of ciprofloxacin on the expression of genes related to liver lipid metabolism in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0046] Fig.21 Section observation of the effect of ciprofloxacin on the expression of monocyte marker CD68 in the liver of mice with diabetic fatty liver induced by STZ combined with high-fat diet (10×).

[0047] Fig. 22To investigate the effects of ciprofloxacin on the expression of genes and proteins related to liver inflammation in mice with diabetic fatty liver induced by STZ combined with high-fat diet.

[0048] Fig.23 Pathological observation of the effect of ciprofloxacin on the liver of mice with diabetic fatty liver induced by STZ and high-fat diet (10×) using Sirius red staining.

[0049] Fig.24 To investigate the effects of ciprofloxacin on the expression of liver fibrosis-related genes and proteins in diabetic fatty liver mice induced by STZ combined with high-fat diet. DETAILED DESCRIPTION

[0050] It is worth noting that the raw materials used in the present invention are all common commercially available products.

[0051] Example Study on the role of ciprofloxacin in metabolism-related fatty liver disease

[0052] 1. Experimental Materials

[0053] 1.1 Mice

[0054] 85 C57BL / 6 male mice, 8-10 weeks old, SPF grade, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., license number: SCXK(Beijing)2021-0011, the optimal temperature was (21±1.5)℃, the relative humidity of the environment was 55±5%, the mice had free access to water, and the mice were fed with ordinary feed before modeling.

[0055] 1.2 Drugs

[0056] Ciprofloxacin (provided by the Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences), positive control drug atorvastatin (catalog number 202010202, purchased from Pfizer), positive control drug metformin (catalog number ACA5354, purchased from Shanghai Bristol-Myers Squibb Pharmaceuticals Co., Ltd.).

[0057] 2. Experimental Methods

[0058] 2.1 Grouping, animal modeling and drug administration

[0059] Two different metabolic-related fatty liver disease mouse models (high-fat diet-induced fatty liver model and diabetic fatty liver model) were established to verify the pharmacological effect of ciprofloxacin on metabolic-related fatty liver disease.

[0060] 2.1.1 Grouping: Forty-five C57BL / 6 mice were divided into the following five groups: solvent control group (NCD), model group (HFD), atorvastatin group (ATV), ciprofloxacin low-dose group (LIGc-L) and ciprofloxacin high-dose group (LIGc-H), with 9 mice in each group.

[0061] High-fat diet-induced fatty liver model: The fatty liver model was induced by feeding the mice with a high-fat, high-fructose diet for 20 weeks. From the 11th week, ligusticum ciprofloxacin (LIGc) and the positive control drug atorvastatin (ATV) were gavage-administered. Both ligusticum ciprofloxacin and atorvastatin were diluted and dissolved with 0.5% sodium carboxymethylcellulose (CMC-Na).

[0062] Dosage method: Atorvastatin group (ATV), low-dose ligusticum ciprofloxacin group (LIGc-L) and high-dose ligusticum ciprofloxacin group (LIGc-H) were gavaged daily for 10 weeks at a standard of 10 mg / kg, 20 mg / kg and 40 mg / kg of mouse body weight, respectively. The solvent control group (NCD) and model group (HFD) were gavaged with an equal volume of sodium carboxymethylcellulose. The weight changes of mice were detected and recorded once a week, and the gavage dose was adjusted. During the experiment, all mice had free access to food and water.

[0063] 2.1.2 Grouping: Forty C57BL / 6 mice were divided into the following five groups: solvent control group (NCD), model group (STZ), metformin group (MET), low-dose ciprofloxacin group (LIGc-L) and high-dose ciprofloxacin group (LIGc-H), with 8 mice in each group.

[0064] Diabetic fatty liver model: Mice were intraperitoneally injected with streptozotocin (STZ) and fed a high-fat diet for 10 weeks to induce a diabetic and non-alcoholic fatty liver model. Ligusticum chuanxiong (LIGc) and the positive control drug metformin (MET) were gavaged from the second week. Both Ligusticum chuanxiong and metformin were diluted and dissolved with 0.5% sodium carboxymethylcellulose (CMC-Na).

[0065] Dosage method: Metformin group (MET), low-dose ligusticum ciprofloxacin group (LIGc-L) and high-dose ligusticum ciprofloxacin group (LIGc-H) were gavaged daily for 8 weeks at a standard of 200 mg / kg, 40 mg / kg and 80 mg / kg of mouse body weight, respectively. The solvent control group (NCD) and model group (HFD) were gavaged with an equal volume of sodium hydroxymethylcellulose. The weight changes of mice were detected and recorded once a week, and the gavage dose was adjusted. During the experiment, all mice had free access to food and water.

[0066] 2.2 Collection of mouse serum

[0067] Blood was collected from mice by removing the eyeballs, and the skin at the blood collection site was gently pressed to fully expose the eyeballs. Blood was squeezed from the tail to the head to increase blood flow. The speed was as fast as possible to prevent hemolysis. When the blood volume was sufficient, the mice were killed by cervical dislocation and laparotomy was performed. After the blood was left to stand for more than 30 minutes, the collected blood was placed in a pre-cooled centrifuge, centrifuged at 5000rmp and 4℃ for 30 minutes, and the upper liquid was aspirated and frozen in a -80℃ refrigerator. The instruments used for sampling were sterilized in advance, and the operation process was sterile. The mouse skin was disinfected and moistened with 75% ethanol to facilitate laparotomy and prevent tissue contamination.

[0068] 2.3 Mouse sampling

[0069] Weigh the mice and record the weight. After anesthetizing the mice, collect blood from the mice by removing the eyeballs. Gently press the skin at the blood collection site to fully expose the eyeballs, squeeze blood from the tail to the head to increase blood flow, as fast as possible to prevent hemolysis. When the blood volume is sufficient, kill the mice by cervical dislocation and perform laparotomy. Fix the plastic foam box with a pin, cut the chest wall of the mice layer by layer at the midline, and after perfusion of the heart with phosphate buffer solution, pinch the marginal membrane structure with tweezers to cut off the entire liver intact, put it in a culture dish, weigh and record the liver weight. Keep the liver at the same site for morphological detection, and put the remaining liver tissue in the corresponding cryopreservation tube, quickly freeze it with liquid nitrogen, and store it in a -80℃ refrigerator for use.

[0070] 2.4 Statistical methods

[0071] All data were expressed as mean ± standard deviation (Mean ± SEM) and statistically analyzed using Graphpad Prism 9.2. The differences between two groups were compared using t-test, and the differences between multiple groups were compared using one-way ANOVA. P < 0.05 indicated statistically significant differences.

[0072] 3. Experimental results

[0073] 3.1 Effects of ciprofloxacin on body weight and liver-to-body ratio in mice with high-fat fructose-induced fatty liver

[0074] The experimental results are as follows Figure 1As shown, compared with the solvent control group (NCD), the body weight of mice in the model group (HFD) increased significantly (P<0.05); compared with the mice in the model group (HFD), the body weight of mice given ciprofloxacin and atorvastatin decreased significantly (P<0.0001). Compared with the solvent control group (NCD), the liver-to-body ratio of mice in the model group (HFD) increased significantly; compared with the model group (HFD), the liver-to-body ratio of mice in the ciprofloxacin group (LIGc-L and LIGc-H) and atorvastatin group (ATV) decreased significantly. The above indicates that ciprofloxacin can reduce the formation of liver fat in mice caused by high-fat diet. Compared with the solvent control group (NCD), # P<0.05; compared with the model group (HFD), **** P<0.0001.

[0075] 3.2 Effect of ciprofloxacin on glucose tolerance in mice with high-fat fructose-induced fatty liver

[0076] OGTT: mice were fasted for 6h (9:00-15:00) the day before being killed, and fasting (i.e. 0h) blood glucose was measured. Oral glucose was administered, and the glucose dose was determined according to the fasting blood glucose (the dose for diabetic mice did not exceed 1g / kg (concentration: 10mg / ml). Too high a dose would cause a spike in blood glucose in mice, which could be lethal and exceed the range of the blood glucose meter; the dose for normal mice did not exceed 2g / kg. Too low a dose would result in no obvious change in the experimental trend). Blood glucose was measured at 15, 30, 60 and 120min after glucose administration (it is recommended to add a 45min detection point if the overall trend of blood glucose in each group of mice has not decreased at 30min, because generally speaking, the experiment has a peak at 15-30min, but the peak may be delayed for various reasons). In addition to strict dosage requirements, this experiment also requires strict control of time. The timing started from the time the first mouse was given glucose (0 minutes and 0 seconds) and the blood glucose of the mouse was tested at the 15th minute. The time for each subsequent mouse was controlled as much as possible to measure blood glucose at the 15th minute after glucose administration, and the 30, 60 and 120min detection points were the same as above. After the experiment, feed and water were added. The measured blood glucose values ​​were statistically analyzed using Graphpad software.

[0077] The experimental results are as follows Figure 2 As shown, the glucose metabolism ability of mice in the model group (HFD) was significantly decreased, while the glucose intolerance of mice in the ciprofloxacin group (LIGc-L and LIGc-H) was significantly improved.

[0078] #### P<0.0001; compared with the model group (HFD), **** P<0.0001.

[0079] 3.3 Effect of ciprofloxacin on insulin tolerance in mice with high-fat fructose-induced fatty liver

[0080] The injection dose of insulin (Article No. 11070-73-8, purchased from Solarbio) was 0.2U / kg. The mice were fasted for 4 hours in the morning and had normal drinking water. Insulin tolerance test was conducted in the afternoon. The mice were weighed and marked with numbers. Blood sugar was measured before insulin injection. The injection amount of insulin was calculated according to body weight. Blood sugar was measured at 0, 15, 30, 60, 90 and 120 minutes. If any mice had hypoglycemia (the mice were cold, stiff, depressed, convulsed, etc.), they were immediately given 10% glucose solution for rescue. After the experiment, new bedding, cage cover, feed and water were replaced. The experimental data were plotted with Graphpad and the area under the curve was calculated.

[0081] The experimental results are as follows Figure 3 As shown, the insulin metabolism ability of mice in the model group (HFD) was significantly decreased, while the insulin resistance of mice in the ciprofloxacin group (LIGc-L and LIGc-H) was significantly improved.

[0082] #### P<0.0001; compared with the model group (HFD), * P<0.05.

[0083] 3.4 Effect of Ciprofloxacin on serum ALT and AST in mice with high-fat fructose-induced fatty liver

[0084] The Nanjing Jiancheng alanine aminotransferase test kit (Cat. No. C009-2-1) and aspartate aminotransferase test kit (Cat. No. C010-2-1) were purchased from Nanjing Jiancheng Bioengineering Institute. Serum ALT and AST were tested according to the instructions.

[0085] Test results such as Figure 4 As shown, in the high-fat diet-induced fatty liver model, the ALT and AST values ​​of the model group (HFD) mice were significantly different from those of the solvent control group (NCD) mice, and the ALT and AST enzyme activities were significantly enhanced, indicating that the model was successfully established and there was obvious liver damage; the ALT and AST values ​​of the mice in the ciprofloxacin administration group (LIGc-L and LIGc-H) were significantly reduced compared with the model group (HFD) mice, indicating that ciprofloxacin has a certain protective effect on liver damage. Compared with the solvent control group (NCD), #### P<0.0001; compared with the model group (HFD), **** P < 0.0001, *** P<0.001.

[0086] 3.5 Effects of ciprofloxacin on hepatic TG indexes in mice with high-fat fructose-induced fatty liver

[0087] Liver TG was extracted by chloroform and methanol 2:1 mixture extraction method, and then tested using Nanjing Jiancheng Triglyceride Test Kit (Cat. No. A110-1-1, purchased from Nanjing Jiancheng Bioengineering Institute) according to the instructions and normalized to liver tissue weight.

[0088] Test results such as Figure 5 As shown, compared with the solvent control group (NCD) mice, the TG content in the liver of the model group (HFD) mice was significantly increased, while the ciprofloxacin administration groups (LIGc-L and LIGc-H) reversed this trend and reduced lipid accumulation in the liver of mice. #### P<0.0001; compared with the model group (HFD),

[0089] **** P<0.0001.

[0090] 3.6 Effect of ciprofloxacin on the histomorphology of fatty liver induced by high-fat fructose

[0091] 3.6.1 Hematoxylin and eosin (H&E) staining: After preheating the oven temperature to 65°C, place the prepared paraffin sections in the oven and bake for 1 hour to melt the wax and make the tissue more closely attached to the glass slide. Dewaxing by immersion in xylene: 20min×2 times, then pass through 100% ethanol 15min×2 times, 95% ethanol 10min, 90% ethanol 5min, 80% ethanol 5min, and distilled water immersion for 5min. Incubate the tissue in hematoxylin working solution for 30s-5min for nuclear staining, differentiate in hydrochloric acid ethanol for 1 / 2s, run water for 15min to return to blue, immerse the tissue in eosin working solution for 1min 25s-2min for cytoplasm staining, and rinse with tap water. Dehydrate the tissue by sequentially using 75% ethanol for 2 seconds, 85% ethanol for 2 seconds, 95% ethanol for 2 seconds, 100% ethanol for 2 seconds, and xylene for 2 seconds. Use filter paper to absorb the xylene adsorbed on the slide, drop neutral resin on the tissue, and cover with a coverslip. Observe under a microscope and collect images for analysis.

[0092] Observation results such as Figure 6As shown in the figure, it can be seen from the H&E staining slides that the liver histopathology of the normal solvent control group (NCD) is normal, the liver lobule structure is clear, the boundary plate is smooth, the hepatocyte cords are arranged regularly, the liver sinusoid structure is clear, and no inflammatory infiltration is observed. No hyperplasia of fibrous connective tissue in the portal area. There is no lipid deposition and fatty degeneration. Severe fatty degeneration can be seen in the model group (HFD), lipid deposition and fatty degeneration appear in a large area of ​​the liver, lipid droplet vacuoles can be seen, and obvious monocyte recruitment can be seen in the liver sinusoids, indicating that lipotoxic inflammatory infiltration occurs in the liver of the model group (HFD) mice. Compared with the model group (HFD), the ballooning degeneration of the liver in the ciprofloxacin administration groups (LIGc-L and LIGc-H) was significantly reduced, and the lipid droplet density was also significantly reduced.

[0093] Oil red O staining: Take out the liver tissue preserved in liquid nitrogen, cut it into 2 cm tissue blocks, and put it into a special small box. Embed with an appropriate amount of OTC, and let the bottom of the box contact liquid nitrogen. After 10 seconds, the tissue freezes into blocks and makes frozen sections with a thickness of 6 μm. Rinse the sections with running water, soak in 60% isopropanol for 2 minutes, dye with oil red O dye for 5 minutes, soak again in 60% isopropanol, rinse with pure water to remove excess isopropanol, restain with hematoxylin for 1 minute, differentiate with hydrochloric acid and alcohol for 5 seconds, turn blue with running water, absorb excess water, seal with glycerol, examine under a microscope, and collect image analysis.

[0094] Observation results such as Figure 6 As shown, there were few red lipid droplets in the liver tissue of mice in the normal solvent control group (NCD). In contrast, the red lipid droplets accumulated in the liver cells of mice in the model group (HFD) were more numerous and larger in area. The area of ​​red lipid droplets in the liver tissue of mice in the ciprofloxacin treatment group (LIGc-L and LIGc-H) was significantly reduced and sparsely distributed. The results show that ciprofloxacin can improve lipid droplet accumulation.

[0095] 3.6.2 Detection of the expression of lipid metabolism-related genes and proteins in the liver by RT-qPCR and protein immunoblotting experiments:

[0096] The experimental method of protein immunoblotting experiment is as follows: a. Sample preparation: Take 40 mg of liver tissue, add RIPA (containing PMSF), freeze grind and homogenize, and stand on ice for 35 minutes to fully lyse. Frozen centrifuge (4℃, 12000rpm) for 25 minutes, and aspirate the supernatant. Finally, denature in a 95℃ metal bath for 15 minutes and store in a -80℃ ultra-low temperature refrigerator. BCA is quantified and the concentration is balanced, and Loading Buffer is added (supernatant: Loading Buffer = 4:1). b. Sample pre-treatment: After taking out the above samples from the ultra-low temperature refrigerator, reheat them in a 95℃ metal bath for 3 minutes and separate them instantly. c. Glue preparation: The glass plate is installed on the glue rack (to ensure that a closed space is formed between the two plates). Mix the gel preparation reagents polyacrylamide, ultrapure water, SDS, ammonium persulfate and TEMED in proportion to prepare separation gel. Pour the gel solution into the glass slide and flatten it with anhydrous ethanol. After it is completely solidified, discard the anhydrous ethanol and prepare concentrated gel (the reagents are the same as above). Insert a tooth comb. d. Electrophoresis: Fix the prepared gel in the transfer card slot and clamp it to form a closed inner tank. Put it in the electrophoresis box as a whole and add electrophoresis solution. The inner tank should be completely filled with electrophoresis solution and slightly overflow. Add it to the appropriate height marked in the electrophoresis box. Pull out the tooth comb and add an equal amount of sample (15-30μg) to the hole at a uniform speed and slowly. After correctly matching the positive and negative poles, add 80 volts of constant voltage to electrophoresize the sample protein until it runs through the concentrated gel, and then increase the pressure to 120 volts until the sample protein runs to the appropriate separation height. e. Transfer: Perform active treatment in methanol solution for 15 minutes, then use electrophoresis technology to remove the concentrate produced by electrophoresis and the bromophenol blue at the bottom, then wash it in the transfer solution, and finally combine the gel produced by electrophoresis and the PVDF membrane tightly and place it in the transfer membrane. Add transfer solution and transfer the membrane at 300 mA constant current for 90 minutes at 4°C. f. Blocking: Take out the membrane, place it in the membrane washing box, and rinse it with TBST 3 times, 10 minutes each time). 5%-15% skim milk powder is blocked at room temperature for 1 hour. The milk powder concentration and blocking time can be adjusted as the room temperature changes. g. Primary antibody incubation: Take out the membrane, place it in a membrane washing box, and rinse with TBST (2-3 times in total, 10-15 minutes each time). After diluting the target primary antibody and internal reference protein (GAPDH or β-actin) to an appropriate concentration (1:5000) in a 50 ml centrifuge tube with primary antibody diluent, stick the membrane protein face inward to the tube wall and incubate at 4°C overnight (more than 10 hours). h. Secondary antibody incubation: Take the membrane out of the container, put it in TBST solution, and wash it 3 times, each time for 10 minutes. Then, dilute the secondary antibody solution to 1:10000, and stick the membrane protein close to the container wall and incubate it at room temperature for 1-1.5 hours. i. Chemiluminescence development: Shake the prepared chemiluminescent solution, soak the membrane in a dark box, shake it for 1-2 minutes, and expose it in the chemiluminescence development system for photography and preservation.

[0097] The experimental method of RT-qPCR experiment is as follows: 1) RNA extraction, a) Cell lysis: first wash the cells with PBS, then add 1mL Trizol to each dish, blow and collect the cells into a new enzyme-free EP tube. b) Tissue lysis: prepare enzyme-free EP tubes, add 1mL Trizol and 2-3 steel beads to each tube, cut a mung bean-sized tissue sample (on dry ice) and add it to the EP tube, and mark the sample number. Put it into the grinder for thorough grinding, shake it vigorously to mix it, and then transfer the tissue homogenate to a new EP tube. c) Phenol-chloroform RNA extraction: add 0.2mL chloroform to each tube of tissue homogenate, shake it on a vortex and mix it, then let it stand for 5min, centrifuge it at 12000rpm and 4℃ for 15min, carefully pipette the upper aqueous phase in the EP tube into a new enzyme-free EP tube. In order to avoid protein impurities, be careful not to inhale the white substance between the aqueous phase and the organic phase. 2) Isopropanol precipitation, add 0.5mL isopropanol to each tube, gently invert upside down to mix, let stand for about 15min, centrifuge at 12000rpm 4℃ for 10min, and RNA can be precipitated. 3) Wash RNA precipitate, wash the precipitate with 75% ethanol prepared with DEPC water, add 1ml 75% ethanol to each tube, invert upside down to resuspend the RNA precipitate, centrifuge at 7500rpm 4℃ for 5min, wash twice, and after the last wash, absorb the remaining ethanol as much as possible (be careful not to absorb the RNA precipitate), then open the lid as soon as possible and put it in the fume hood to air dry at room temperature, and finally add appropriate DEPC water to dissolve RNA (generally 20-50L). 4) RNA quality inspection, a) RNA concentration detection, control the RNA concentration at 200-2000ng / μL. If the concentration is too high, add appropriate DEPC water to dilute it. b) RNA purity detection. At pH = 7-8.5, an A260 / A280 ratio of about 1.8 or 2.0 indicates that the RNA purity is good. c) RNA integrity test: RNA integrity is determined by agarose gel electrophoresis. There is no tailing in the lane, and the complete total RNA presents clear bands, namely 28S and 18S rRNA. The intensity of the 28s rRNA band is twice as bright as the 18S rRNA band. 5) Use a reverse transcription kit to perform amplification cycles on the extracted RNA samples (conditions: 37°C for 15 minutes, 85°C for 5 seconds) to obtain cDNA. After mixing the samples evenly according to the qPCR loading system, add them to the 384 qPCR well plate in the loading order. Place in a fluorescent quantitative PCR instrument (Roche LightCycler 480) for detection. After the test, follow formula 2 -ΔΔCT Calculate the relative mRNA value of each sample.

[0098] The experimental results are as follows Figure 7As shown, compared with the solvent control group (NCD), the lipid metabolism-related genes Fasn and Fabp1 in the model group (HFD) mice were significantly increased, the genes Ppar-a and Atgl were significantly decreased, and the protein Ppar-a was significantly decreased. Compared with the model group (HFD), the mice in the ciprofloxacin administration groups (LIGc-L and LIGc-H) significantly reduced the expression of lipid metabolism-related genes Fasn and Fabp1, significantly increased the expression of genes Ppar-a and Atgl, significantly increased the protein Ppar-a, and reduced the expression of protein PPAR-γ. Compared with the solvent control group (NCD), ### P < 0.001, #### P<0.0001; compared with the model group (HFD), * P<0.05, ** P<0.01, *** P<0.001.

[0099] 3.7 Effect of ciprofloxacin on high-fat fructose-induced fatty liver inflammation

[0100] Metabolic inflammation is an important factor in hepatocyte damage in non-alcoholic fatty liver disease. To further confirm the comprehensive protective effect of ciprofloxacin on metabolic-related fatty liver disease, the metabolic inflammation mediated by liver lipotoxicity in mice with metabolic-related fatty liver disease was observed experimentally. CD68 is the most widely used monocyte marker in routine examinations and is also a transmembrane glycoprotein. Its positive area can be used to reflect the degree of liver inflammatory infiltration.

[0101] 3.7.1 Detection of monocyte marker CD68 expression by immunohistochemistry: The specific steps are as follows: take liver tissue sections from each group of mice, dewax them according to xylene and decreasing concentrations of alcohol; soak in distilled water for 5 minutes; fix with citrate for 15 minutes, cool to room temperature; soak in distilled water for 2 minutes; place at room temperature with 3% hydrogen peroxide for 10 minutes; wash with PBS three times; block with 1% BSA for 1 hour; wash with PBS three times; add primary antibody CD68, incubate at 4°C overnight; wash with PBS three times; add secondary antibody and incubate at room temperature for 2 hours; wash with PBS three times; develop color with DAB; rinse with tap water for 3 minutes; stain with hematoxylin for 1 minute; rinse with tap water for 5 minutes; dehydrate with increasing concentrations of ethanol, make transparent with xylene, and seal with neutral gum after air drying; observe the monocyte marker CD68 in the liver tissue section seal.

[0102] Observation results such as Figure 8 As shown, compared with the solvent control group (NCD), the CD68 positive staining in the model group (HFD) mice was significantly increased, that is, the infiltration of monocytes was significantly increased; while the CD68 expression in the ciprofloxacin administration groups (LIGc-L and LIGc-H) was significantly reduced, indicating that ciprofloxacin can reduce the degree of inflammatory infiltration in the process of high-fat fructose-induced fatty liver.

[0103] 3.7.2 According to the experimental method described in 3.6.2 above, the expression of inflammation-related genes and proteins in the liver was detected by RT-qPCR and protein immunoblotting. Fig. 9 As shown, compared with the solvent control group (NCD), the inflammatory genes (IL-6, IL-1b, TNF-α) and protein IL-1β in the model group (HFD) mice were significantly increased. Compared with the model group (HFD), the treatment of the ciprofloxacin administration groups (LIGc-L and LIGc-H) significantly reduced the expression of related inflammatory genes and proteins. #### P<0.0001; compared with the model group (HFD), *** P < 0.001,

[0104] ** P<0.01, * P<0.05.

[0105] 3.8 Effect of ciprofloxacin on high-fat fructose-induced fatty liver fibrosis

[0106] 3.8.1 Observation of liver collagen deposition by Sirius red staining: The specific steps are as follows: Preheat the oven temperature to 65°C and bake the slides for 1 hour. Dewaxing: xylene 20 minutes → xylene 20 minutes → anhydrous ethanol 15 minutes → anhydrous ethanol 15 minutes → 95% ethanol 10 minutes → 90% ethanol 5 minutes → 80% ethanol 5 minutes. Let stand in distilled water for 5 minutes (this step cannot be omitted, otherwise it will not be stained). Stain with Sirius red (brand: sigma) for 30 minutes (avoid light, drip staining, about 20-30μL for each tissue), rinse with tap water. Dehydration: 75% ethanol 2 seconds → 85% ethanol 2 seconds → 95% ethanol 2 seconds → 100% ethanol 2 seconds → xylene 2 seconds → xylene 2 seconds. Air dry and seal with neutral gum.

[0107] Observation results such as Fig.10 As shown, a large amount of collagen deposition was observed in the model group (HFD), and this collagen deposition was significantly improved in the ciprofloxacin-treated groups (LIGc-L and LIGc-H), indicating that ciprofloxacin has the effect of improving liver fibrosis.

[0108] 3.8.2 According to the experimental method described in 3.6.2 above, the expression of profibrosis-related genes in the liver was detected by RT-qPCR experiment. The test results are as follows Fig.11 As shown, compared with the solvent control group, the fibrosis gene Tgf-β1 in the model group (HFD) was significantly increased, and compared with the model group (HFD), the treatment with ciprofloxacin administration groups (LIGc-L and LIGc-H) significantly reduced the expression of pro-fibrosis genes. ####P<0.0001; compared with the model group (HFD),

[0109] *** P < 0.001, ** P<0.01.

[0110] 3.9 Effects of ciprofloxacin on body weight and liver-to-body ratio in diabetic fatty liver mice induced by STZ combined with high-fat diet

[0111] Depend on Fig.12 It can be seen that compared with the solvent control group (NCD), the body weight of mice in the model group (STZ) increased significantly (P<0.001); compared with the model group (STZ), the body weight of mice given high-dose ciprofloxacin (LIGc-H) and metformin (MET) decreased significantly (P<0.01). Compared with the solvent control group (NCD), the liver-to-body ratio of the model group (STZ) increased significantly, and compared with the model group (STZ), the liver-to-body ratio of mice in the ciprofloxacin groups (LIGc-L and LIGc-H) decreased significantly, indicating that ciprofloxacin can reduce the formation of liver fat in mice caused by high-fat diet. Compared with the solvent control group (NCD), ### P < 0.001, ## P<0.01; compared with the model group (STZ), ** P<0.01, * P<0.05.

[0112] Depend on Fig.13 It can be seen that the liver size and weight of mice in the model group (STZ) were significantly increased compared with the solvent control group (NCD), while the administration of ciprofloxacin (LIGc-L and LIGc-H) significantly reversed this trend.

[0113] 3.10 Effects of Ciprofloxacin on fasting blood glucose in mice with diabetic fatty liver induced by STZ combined with high-fat diet

[0114] Measurement of fasting blood glucose: Fasting blood glucose was measured on all mice 24 hours after the last administration. The mice were fasted at 19:00 the night before the measurement and blood glucose was measured at 7:00 the next morning. Blood was collected from the end of the mouse tail under standard temperature and humidity conditions to obtain fasting blood glucose.

[0115] Test results such as Fig.14 As shown, the blood glucose results after eight weeks of administration showed that compared with the model group (STZ), the positive drugs metformin (MET) and ciprofloxacin (LIGc-L and LIGc-H) both had a significant hypoglycemic effect. Compared with the solvent control group (NCD), ## P<0.01; compared with the model group (STZ), *** P < 0.001, ** P<0.01.

[0116] 3.11 Effects of Ciprofloxacin on glucose tolerance in diabetic fatty liver mice induced by STZ combined with high-fat diet

[0117] Oral gavage of glucose was performed, and the glucose dose was determined by fasting blood glucose (the dose for diabetic mice did not exceed 1g / kg (concentration: 10mg / ml). Too high a dose would cause a spike in blood glucose in mice, which could be lethal and exceed the range of the blood glucose meter. The dose for normal mice did not exceed 2g / kg. Too low a dose would not produce obvious experimental trends). Blood glucose was measured at 30, 60, 90, and 120 minutes after administration of glucose. Other experimental steps were the same as in 3.2.

[0118] The experimental results are as follows Fig.15 As shown, the glucose metabolism ability of mice in the model group (STZ) was significantly decreased, while the glucose intolerance of mice in the ciprofloxacin group (LIGc-L and LIGc-H) was significantly improved.

[0119] ### P<0.001; compared with the model group (STZ), ** P<0.01, * P<0.05.

[0120] 3.12 Effect of Ciprofloxacin on Insulin Resistance in Mice with Diabetic Fatty Liver Induced by STZ and High-Fat Diet

[0121] The injection dose of insulin (catalog number 11070-73-8, purchased from Solarbio) was 0.2 U / kg, and blood glucose was measured at 0, 15, 30, 45 and 60 min. The other experimental steps were consistent with 3.3.

[0122] The experimental results are as follows Fig.16 As shown, the insulin metabolism ability of mice in the model group (STZ) was significantly decreased, while the insulin resistance of mice in the ciprofloxacin group (LIGc-L and LIGc-H) was significantly improved.

[0123] ### P<0.001; compared with the model group (STZ), *** P < 0.001, ** P<0.01, * P<0.05.

[0124] 3.13 Effects of Ciprofloxacin on serum ALT and AST in mice with diabetic fatty liver induced by STZ combined with high-fat diet

[0125] The experimental steps are the same as 3.4.

[0126] Test results such as Fig.17 As shown in the figure, in the model of diabetes combined with non-alcoholic fatty liver disease, the ALT and AST values ​​of the model group (STZ) were significantly different from those of the solvent control group (NCD); the ALT and AST values ​​of the ciprofloxacin-treated groups (LIGc-L and LIGc-H) were significantly reduced compared with the model group (STZ), indicating that ciprofloxacin has a certain protective effect on liver damage. Compared with the solvent control group (NCD), ### P<0.001; compared with the model group (STZ), *** P<0.001.

[0127] 3.14 Effects of Ciprofloxacin on TG in the Liver of Mice with Diabetic Fatty Liver Induced by STZ Combined with High-Fat Diet

[0128] The experimental steps are the same as 3.5.

[0129] Test results such as Fig.18 As shown, compared with the solvent control group (NCD) mice, the TG content in the liver of the model group (STZ) mice was significantly increased, while the TG content in the liver of the mice in the ciprofloxacin administration group (LIGc-L and LIGc-H) was lower than that in the model group, which reduced the lipid accumulation in the liver of mice. ## P<0.01; compared with the model group (STZ), * P<0.05, ** P<0.01.

[0130] 3.15 Effect of Ciprofloxacin on the Histomorphology of Diabetic Fatty Liver Induced by STZ Combined with High-Fat Diet

[0131] 3.15.1 Observation of liver tissue sections:

[0132] Hematoxylin and eosin (H&E) staining: The experimental steps are the same as 3.6.1.

[0133] Observation results such as Fig.19 As shown, the liver histopathology of the solvent control group (NCD) mice was normal, without lipid deposition and steatosis. The livers of the model group (STZ) mice showed significant lipid deposition and steatosis, and obvious monocyte recruitment was observed in the hepatic sinusoids, indicating that lipotoxic inflammatory infiltration occurred in the livers of the model group (STZ) mice. Compared with the model group (STZ), the liver ballooning degeneration and inflammatory infiltration of the ciprofloxacin-treated groups (LIGc-L and LIGc-H) were significantly reduced. The experimental results show that the ciprofloxacin-treated groups (LIGc-L and LIGc-H) effectively improved the steatosis and lipotoxic damage of STZ-induced diabetes combined with non-alcoholic fatty liver.

[0134] 3.15.2 Detect the expression of lipid metabolism-related genes in the liver by RT-qPCR experiment: The experimental steps are consistent with 3.6.2.

[0135] The results are as follows Fig. 20 As shown, compared with the solvent control group (NCD), the lipid metabolism genes Srebp-1c, Hmgcr, ACCα, Scd1 and Cd36 in the model group (STZ) were significantly increased, and the gene Atgl was significantly decreased. Compared with the model group (STZ), the ciprofloxacin administration groups (LIGc-L and LIGc-H) significantly reduced the expression of lipid metabolism-related genes Srebp-1c, Hmgcr, ACCα, Scd1 and Cd36, and significantly increased the expression of gene Atgl. Compared with the solvent control group (NCD), ## P<0.01, # P<0.05; compared with the model group (STZ), *** P < 0.001, ** P<0.01,

[0136] * P<0.05.

[0137] 3.16 Effect of Ciprofloxacin on STZ- and high-fat diet-induced diabetic fatty liver inflammation

[0138] 3.16.1 Detection of monocyte marker CD68 expression by immunohistochemistry: The experimental steps are the same as 3.7.1.

[0139] Observation results such as Fig.21 As shown in the figure, compared with the model group (STZ), the ciprofloxacin-treated groups (LIGc-L and LIGc-H) significantly reduced the positive staining area of ​​the central vein and hepatic lobule in the liver of mice with diabetic fatty liver. This indicates that ciprofloxacin can effectively inhibit the occurrence of liver metabolic inflammation in mice with diabetes and non-alcoholic fatty liver under metabolic stress.

[0140] 3.16.2 Detect the expression of inflammation-related genes and proteins in the liver by RT-qPCR and protein immunoblotting experiments: The experimental steps are consistent with 3.7.2.

[0141] Test results such as Fig. 22 As shown, compared with the solvent control group (NCD), the model group (STZ) had significantly increased inflammation-related genes (Il-1b, Il-6, Cxcl10, and Ccl2) and inflammation-related protein IL-1β, and compared with the model group (STZ), the ciprofloxacin administration groups (LIGc-L and LIGc-H) significantly reduced the expression of inflammation-related genes and proteins. ##P<0.01; compared with the model group (STZ), *** P < 0.001, ** P<0.01, * P<0.05.

[0142] Effect of 3.17 Ciprofloxacin on diabetic fatty liver fibrosis induced by STZ combined with high-fat diet

[0143] 3.17.1 Observation of collagen deposition in mouse liver by Sirius red staining: The experimental steps are the same as 3.8.1.

[0144] Observation results such as Fig.23 As shown in the figure, the Sirius Red positive area was obvious in the model group (STZ), while the positive area decreased after treatment with ciprofloxacin and the positive drug metformin (MET), indicating that collagen deposition was significantly reduced, indicating that ciprofloxacin has the effect of improving liver fibrosis. It is worth noting that the improvement effect of the high-dose ciprofloxacin group (LIGc-H) was significantly better than that of the positive drug metformin (MET).

[0145] 3.17.2 Detect the expression of profibrosis-related genes and proteins in the liver by RT-qPCR and protein immunoblotting: The experimental steps are consistent with 3.8.2.

[0146] Test results such as Fig.24 As shown, compared with the solvent control group (NCD), the model group had significantly increased fibrosis genes (Col1a1, Tgf-β1 and Timp1) and profibrotic protein Collagen-1, and compared with the model group (STZ), the ciprofloxacin administration groups (LIGc-L and LIGc-H) significantly reduced the expression of profibrotic genes and proteins. ## P<0.01; compared with the model group (STZ), *** P < 0.001, ** P<0.01, * P<0.05.

[0147] In summary, the technical solution of the present invention has been demonstrated to have a significant improvement effect on liver damage, insulin resistance, glucose and lipid metabolism disorders, inflammatory damage and fibrosis in two metabolism-related fatty liver disease models.

[0148] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. The use of ciprofloxacin in the preparation of drugs for preventing and / or treating metabolism-related fatty liver disease.

2. The use according to claim 1, characterized in that: The ciprofloxacin is the main active ingredient in the drug for preventing and treating non-alcoholic fatty liver disease and / or diabetes combined with non-alcoholic fatty liver disease induced by a high-fat diet.

3. The use according to claim 1, characterized in that: The method for preventing and / or treating metabolic-related fatty liver disease is embodied in at least one of the following aspects: 1) Inhibit hepatic lipogenesis, lipid deposition and / or liver damage; 2) Reduce fasting blood sugar levels; 3) Improve glucose intolerance and insulin resistance; 4) Improve fatty degeneration and lipotoxic damage; 5) Reduce the expression of genes related to lipid metabolism, liver inflammation and / or fibrosis.

4. The use according to claim 3, characterized in that: The lipid metabolism related genes include one or more of Pparα, Fasn, Fabp1, Atgl, Srebp-1c, Hmgcr, Accα, Scd1 and Cd36.

5. The use according to claim 3, characterized in that: The liver inflammation-related genes include one or more of IL-6, IL-1b, TNF-α, Cxcl10 and Ccl2.

6. The use according to claim 3, characterized in that: The fibrosis-related genes include one or more of Tgf-β1, Col1a1 and Timp1.

7. The use according to any one of claims 1 to 6, characterized in that: Ciprofloxacin is the only active ingredient in the drug.

8. The use according to claim 1, characterized in that: The drug comprises pharmaceutically acceptable excipients, which include one or more of surfactants, buffer substances, disintegrants, binders, fillers, lubricants, solubilizers, flavoring agents and colorants.

9. The use according to claim 1, characterized in that: The dosage form of the drug is tablet, pill, capsule, granule, powder or liquid.

10. The use according to claim 1, characterized in that: The drug is administered by the following routes: oral, subcutaneous, intravenous injection or sustained release form.

Citation Information

Patent Citations

  • Compound as liver protective agent and compositions

    CN101654393A

  • Method for preparing Ligusticum wallichii lactone extract having anti-liquid-accumulation activity, and use

    CN102824382A

  • Application of cyclopropyl lactam of radix ligustici sinensis in preparation of drugs for preventing and treating acute or chronic liver injuries and hepatic fibrosis

    CN109939108A